200780 — BCWorldPharm Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩51bn
- KR₩130bn
- KR₩75bn
- 49
- 65
- 31
- 45
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS/A | ARS/A | ARS | ARS | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 51,497 | 57,030 | 62,079 | 72,703 | 75,111 |
Cost of Revenue | |||||
Gross Profit | 17,803 | 20,496 | 20,098 | 27,403 | 31,963 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 52,607 | 59,129 | 63,613 | 70,905 | 68,746 |
Operating Profit | -1,110 | -2,099 | -1,534 | 1,797 | 6,365 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2,572 | -2,830 | -2,936 | -1,523 | 1,206 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1,739 | -2,194 | -2,978 | 59.8 | 2,892 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -1,553 | -1,580 | -1,843 | 281 | 2,634 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -1,553 | -1,580 | -1,843 | 281 | 2,634 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -180 | -201 | -216 | 37.9 | 308 |
Dividends per Share |